The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

Viewing identity through the lens of the seasons underscores the fluid, evolving nature of who we are. Just as the seasons ...

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo ...

That is what standing up to cancer means to me: not just surviving, but living fully, deeply, and purposefully, showing the ...

This guide for newly diagnosed patients provides key information to help you understand your options and have informed ...

This guide is designed to help you understand liver cancer and equip you with the right questions to ask your medical team.

Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope ...

Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among ...

Susan G. Komen is marking a significant milestone in the effort to improve care and outcomes for people facing inflammatory ...

Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer ...